cancers

2022 BEST PAPER AWARD WINNERS

Dear Colleagues,

We are pleased to announce the winners of the *Cancers* 2022 Best Paper Award. All papers published from 1 January 2022 to 31 December 2022 in *Cancers* were considered for the award. After a thorough evaluation of the originality and significance of the papers, citations and downloads, four winners were selected.

Two Reviews:

Chemotherapy Side-Effects: Not All DNA Damage Is Equal
By Winnie M. C. van den Boogaard, Daphne S. J. Komninos and Wilbert P. Vermeij
Cancers. **2022**, *14*(3), 627; doi: 10.3390/cancers14030627

Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy
By Yang Zhou, Miao Li, Kuangyi Zhou, James Brown, Tasha Tsao, Xinjian Cen, Tiffany Husman, Aarushi Bajpai, Zachary Spencer Dunn and Lili Yang
Cancers. **2022**, *14*(9), 2266; doi: 10.3390/cancers14092266

Two Articles:

Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells
By Timothy Crook, Robert Leonard, Kefah Mokbel, Alastair Thompson, Michael Michell, Raymond Page, Ashok Vaid, Ravi Mehrotra, Anantbhushan Ranade, Sewanti Limaye, Darshana Patil, Dadasaheb Akolkar, Vineet Datta, Pradip Fulmali, Sachin Apurwa, Stefan Schuster, Ajay Srinivasan and Rajan Datar
Cancers. **2022**, *14*(14), 3341; doi: 10.3390/cancers14143341

T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity
By Nadja Sailer, Ina Fetzer, Melanie Salvermoser, Monika Braun, Doris Brechtefeld, Christian Krendl, Christiane Geiger, Kathrin Mutze, Elfriede Noessner, Dolores J. Schendel, Maja Bürdek, Susanne Wilde and Daniel Sommermeyer
Cancers. **2022**, *14*(8), 1998; doi: 10.3390/cancers14081998

Each winner will receive CHF 500, an electronic certificate and a chance to publish a paper in *Cancers* in 2024 following peer review.

Please join us in congratulating the winners of the *Cancers* 2022 Best Paper Award. We would also like to take this opportunity to thank all of our authors for your continued support of *Cancers.*